Scholar Rock Holding Co. Expected to Post Q2 2022 Earnings of ($0.82) Per Share (NASDAQ:SRRK)

Scholar Rock Holding Co. (NASDAQ:SRRKGet Rating) – Research analysts at Jefferies Financial Group increased their Q2 2022 EPS estimates for shares of Scholar Rock in a report issued on Monday, June 20th. Jefferies Financial Group analyst M. Yee now expects that the company will post earnings per share of ($0.82) for the quarter, up from their prior estimate of ($0.88). The consensus estimate for Scholar Rock’s current full-year earnings is ($2.91) per share. Jefferies Financial Group also issued estimates for Scholar Rock’s Q3 2022 earnings at ($0.60) EPS, Q4 2022 earnings at ($0.62) EPS, FY2022 earnings at ($2.30) EPS, Q1 2023 earnings at ($0.70) EPS, Q2 2023 earnings at ($0.70) EPS, Q3 2023 earnings at ($0.72) EPS, Q4 2023 earnings at ($0.74) EPS and FY2023 earnings at ($2.87) EPS.

A number of other research analysts have also recently weighed in on SRRK. BMO Capital Markets dropped their price objective on shares of Scholar Rock from $74.00 to $55.00 in a research note on Tuesday, May 17th. HC Wainwright initiated coverage on shares of Scholar Rock in a research note on Wednesday, March 23rd. They set a “buy” rating and a $24.00 price objective for the company. Piper Sandler dropped their price objective on shares of Scholar Rock from $28.00 to $19.00 and set an “overweight” rating for the company in a research note on Thursday. Wedbush lowered their target price on shares of Scholar Rock from $50.00 to $33.00 and set a “na” rating for the company in a research note on Tuesday, May 17th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Scholar Rock from $46.00 to $37.00 in a research note on Tuesday, May 24th.

Shares of SRRK opened at $6.23 on Thursday. The company has a debt-to-equity ratio of 0.25, a current ratio of 6.85 and a quick ratio of 6.85. The firm has a 50 day simple moving average of $6.26 and a 200-day simple moving average of $14.08. Scholar Rock has a 1-year low of $4.32 and a 1-year high of $44.95. The stock has a market cap of $219.93 million, a price-to-earnings ratio of -2.05 and a beta of 0.62.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Eaton Vance Management boosted its holdings in shares of Scholar Rock by 2.9% in the 4th quarter. Eaton Vance Management now owns 25,892 shares of the company’s stock valued at $643,000 after purchasing an additional 728 shares during the last quarter. BNP Paribas Arbitrage SA boosted its holdings in shares of Scholar Rock by 15.7% in the 4th quarter. BNP Paribas Arbitrage SA now owns 5,880 shares of the company’s stock valued at $146,000 after purchasing an additional 796 shares during the last quarter. Credit Suisse AG boosted its holdings in shares of Scholar Rock by 6.5% in the 3rd quarter. Credit Suisse AG now owns 14,132 shares of the company’s stock valued at $466,000 after purchasing an additional 868 shares during the last quarter. First Mercantile Trust Co. acquired a new position in shares of Scholar Rock in the 3rd quarter valued at $59,000. Finally, DekaBank Deutsche Girozentrale boosted its holdings in shares of Scholar Rock by 10.2% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 19,400 shares of the company’s stock valued at $251,000 after purchasing an additional 1,800 shares during the last quarter. Institutional investors own 84.22% of the company’s stock.

Scholar Rock Company Profile (Get Rating)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

Read More

Earnings History and Estimates for Scholar Rock (NASDAQ:SRRK)

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.